International Randomized Phase III Study of Elacytarabine Versus Investigator Choice in Patients With Relapsed/Refractory Acute Myeloid LeukemiaROBOZ, Gail J; ROSENBLAT, Todd; HILLS, Robert et al.Journal of clinical oncology. 2014, Vol 32, Num 18, pp 1919-1926, issn 0732-183X, 8 p.Article

Phase I and pharmacokinetic study of elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, in adults with refractory hematological malignanciesGILES, F. J; VEY, N; RIZZIERI, D et al.Leukemia. 2012, Vol 26, Num 7, pp 1686-1689, issn 0887-6924, 4 p.Article

Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemiaO'BRIEN, Susan; RIZZIERI, David A; STAUDACHER, Karin et al.British journal of haematology. 2012, Vol 158, Num 5, pp 581-588, issn 0007-1048, 8 p.Article

A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapyPIGNATA, S; AMANT, F; CANNELLA, L et al.Cancer chemotherapy and pharmacology. 2011, Vol 68, Num 5, pp 1347-1353, issn 0344-5704, 7 p.Article